ArticleNature2024
A novel antibiotic class targeting the lipopolysaccharide transporter.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 164 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 2 pooled it
46.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 274 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- Can we escape from top-priority ESKAPE pathogens?Emerging microbes & infections · 2026Review
- Broad-Spectrum, Cell Envelope-Active Marinocyclin Antibiotics From a Coral-Derived Bacterium Are Effective Against Colistin-Resistant Bacteria.Angewandte Chemie (International ed. in English) · 2026Article
- Trends towards multidrug-resistant bacteria: heterocyclic compounds containing antimicrobial agents: review.RSC advances · 2026Review
- Article
- Article
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Review
- Deep learning extracts MoA-specific signatures from high-throughput images of chemically and genetically perturbedScience advances · 2026Article
- Article
- Discovery of antimicrobial peptides from incomplete biosynthetic gene clusters to combat multidrug-resistant bacteria.Cell reports. Medicine · 2026Article
- Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens.ACS infectious diseases · 2026Article
- TheInternational journal of molecular sciences · 2026Article
- Deep learning recognises antibiotic modes of action from brightfield images.Nature communications · 2026Article
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Identification of Antibacterial Cyclic Peptides with a High-Throughput Cell-Based Dropout Screen.Journal of the American Chemical Society · 2026Article
- Rapid delineation ofMicrobiology spectrum · 2026Article
- Non-canonical gene amplifications facilitate adaptive evolution in bacteria.Nature microbiology · 2026Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
40 authors at 4 institutions in 5 countries.
Claudia Zampaloni *Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0009-0007-8690-6733
Patrizio Mattei *Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-2217-8833
Konrad Bleicher *Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Lotte WintherRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Claudia ThäteRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Christian BucherRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-4808-2557
Jean-Michel AdamRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Alexander AlanineRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-3448-9866
Kurt E AmreinRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Vadim BaidinDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0002-6257-1226
Christoph BieniossekRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Caterina BissantzRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Franziska BoessRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-3886-8193
Carina CantrillRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-8992-372X
Thomas ClairfeuilleRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Fabian DeyRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-4903-2869
Patrick Di GiorgioRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Pauline du CastelRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
David DylusRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Pawel DzygielRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0009-0006-4722-4070
Antonio FeliciDiscovery Microbiology, Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.ORCID 0000-0003-2918-5427
Fernando García-AlcaldeRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-5432-556X
Andreas HaldimannRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Matthew LeipnerRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-0079-140X
Semen LeynInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-9886-9120
Séverine LouvelRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Pauline MissonRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Andrei OstermanInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-3810-9824
Karanbir PahilDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0003-0247-5934
Sébastien RigoRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0003-3598-2123
Adrian SchäublinRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Sebastian ScharfRoche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Petra SchmitzRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Theodor StollRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Andrej TraunerRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0000-0002-6260-9829
Sannah ZoffmannRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.ORCID 0009-0000-8631-4462
Daniel KahneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0002-8296-1424
John A T YoungRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Michael A LobritzRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. michael.lobritz@roche.com.ORCID 0000-0003-3885-4936
Kenneth A BradleyRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. kenneth.bradley@roche.com.ORCID 0000-0002-4757-5122
Roche (Switzerland) · CHHarvard University · USSanford Burnham Prebys Medical Discovery Institute · USAptuit (Italy) · IT
Funding
Outer Membrane Biogenesis: New Antibiotic TargetsR01AI081059 · NIAID · HARVARD UNIVERSITY · PI Daniel Kahne · 2009 to 2026
$9.5MStudies on the Biological Mechanisms of AntibioticsR01AI149778 · NIAID · HARVARD UNIVERSITY · PI Daniel Kahne · 2020 to 2026
$4.7MComparative resistomics of Gram-negative bacterial pathogensR01AI167977 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ANDREI L OSTERMAN · 2022 to 2026
$3.7MNIAID NIH HHS R01 AI081059NIAID NIH HHS R01 AI149778NIAID NIH HHS R01 AI167977
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options
Indexed as
Anti-Bacterial AgentsLipopolysaccharidesMembrane Transport ProteinsAcinetobacter baumanniiAcinetobacter InfectionsAnimalsBiological TransportDisease Models, AnimalDrug DevelopmentDrug Resistance, Multiple, BacterialHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsLipopolysaccharidesMembrane Transport Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.